Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Cash (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Change in Cash for 7 consecutive years, with -$13.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 219.88% year-over-year to -$13.3 million, compared with a TTM value of $120.4 million through Dec 2025, up 256.6%, and an annual FY2025 reading of $120.4 million, up 256.6% over the prior year.
  • Change in Cash was -$13.3 million for Q4 2025 at Summit Therapeutics, up from -$59.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $526.6 million in Q4 2022 and bottomed at -$577.6 million in Q1 2023.
  • Average Change in Cash over 5 years is $8.0 million, with a median of -$3.6 million recorded in 2021.
  • The sharpest move saw Change in Cash surged 6327.22% in 2022, then crashed 10307.42% in 2023.
  • Year by year, Change in Cash stood at -$8.5 million in 2021, then soared by 6327.22% to $526.6 million in 2022, then plummeted by 90.96% to $47.6 million in 2023, then crashed by 76.72% to $11.1 million in 2024, then crashed by 219.88% to -$13.3 million in 2025.
  • Business Quant data shows Change in Cash for SMMT at -$13.3 million in Q4 2025, -$59.3 million in Q3 2025, and $86.3 million in Q2 2025.